Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29190539 | 0.79 | ALDH1A1 (0.36) | SMN1; SMN2MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL18703734 | 0.76 | ALDH1A1 (0.36) | MAPTALDH1A1POLBCASP6 | |
| SCHEMBL28774690 | 0.75 | MAPT (0.40) | SMN1; SMN2MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL15648743 | 0.71 | MAPT (0.36) | SMN1; SMN2MAPTALDH1A1POLBCASP6 | |
| SCHEMBL29190624 | 0.71 | BTK (0.33) | SMN1; SMN2ALDH1A1KDM4ELMNAGLA | |
| SCHEMBL14785263 | 0.70 | HTR5A (0.39) | SMN1; SMN2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL20162223 | 0.70 | RPS6KA5 (0.35) | SMN1; SMN2MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL15944113 | 0.69 | NPC1 (0.43) | MAPTL3MBTL1KMT2A | |
| SCHEMBL20521619 | 0.69 | ALDH1A1 (0.38) | SMN1; SMN2MAPTALDH1A1KDM4EPOLB | |
| SCHEMBL19966317 | 0.68 | ALDH1A1 (0.36) | SMN1; SMN2MAPTALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028405-A1 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| EP-2234986-A2 | SULFAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080638-A2 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028405-A1 | SULFAMIDES AS ZAP-70 INHIBITORS | ZAP70, SYK, LCK | SMN1; SMN2 2983/4885MAPT 4787/4885ALDH1A1 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.